SciSparc Unit NeuroThera Labs Issues Update On Its Clinical Trial Program Evaluating SCI-110 For Treatment Of Tourette Syndrome In Adults; Now Advancing Toward Patient Enrollment In Its Phase IIb Clinical Trial For TS, With Investigational Product Shipments To Study Sites Expected In The Near Term

Loading news article.

SciSparc Unit NeuroThera Labs Issues Update On Its Clinical Trial Program Evaluating SCI-110 For Treatment Of Tourette Syndrome In Adults; Now Advancing Toward Patient Enrollment In Its Phase IIb Clinical Trial For TS, With Investigational Product Shipments To Study Sites Expected In The Near Term | WAPE

SciSparc Unit NeuroThera Labs Issues Update On Its Clinical Trial Program Evaluating SCI-110 For Treatment Of Tourette Syndrome In Adults; Now Advancing Toward Patient Enrollment In Its Phase IIb Clinical Trial For TS, With Investigational Product Shipments To Study Sites Expected In The Near Term

Article summary

Related companies

Analyzed by WAPE AI.

Comments —